Related Experiment Video
Updated: Jan 24, 2026

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
The current state of molecular testing in the treatment of patients with solid tumors, 2019
Wafik S El-Deiry1, Richard M Goldberg2, Heinz-Josef Lenz3
1Associate Dean for Oncologic Sciences, Warren Alpert Medical School; Director, Joint Program in Cancer Biology, Brown University and the Lifespan Cancer Institute; Professor of Pathology & Laboratory Medicine and Professor of Medical Science, Brown University, Providence, RI.
Abstract:
The world of molecular profiling has undergone revolutionary changes over the last few years as knowledge, technology, and even standard clinical practice have evolved. Broad molecular profiling is now nearly essential for all patients with metastatic solid tumors. New agents have been approved based on molecular testing instead of tumor site of origin. Molecular profiling methodologies have likewise changed such that tests that were performed on patients a few years ago are no longer complete and possibly inaccurate today. As with all rapid change, medical providers can quickly fall behind or struggle to find up-to-date sources to ensure he or she provides optimum care. In this review, the authors provide the current state of the art for molecular profiling/precision medicine, practice standards, and a view into the future ahead.
Insights
Molecular profiling is now essential for metastatic solid tumors, with new treatments approved based on genetic testing, not tumor location. This review covers current standards and future directions in precision medicine.
Area of Science:
- Oncology
- Genetics
- Clinical Practice
Background:
- Molecular profiling has rapidly evolved, becoming crucial for treating metastatic solid tumors.
- New cancer therapies are increasingly approved based on molecular testing results, shifting focus from tumor site.
- Outdated molecular profiling tests may yield inaccurate results, necessitating updated approaches.
Purpose of the Study:
- To provide an up-to-date overview of molecular profiling and precision medicine.
- To discuss current practice standards in molecular testing for cancer patients.
- To offer insights into the future of molecular profiling in clinical oncology.
Main Methods:
- Review of current literature and clinical practice guidelines.
- Analysis of recent advancements in molecular profiling technologies.
- Synthesis of information on newly approved molecularly targeted therapies.
Main Results:
- Broad molecular profiling is now a near-essential component of care for metastatic solid tumors.
- Treatment decisions and drug approvals are increasingly driven by molecular alterations rather than tumor histology.
- Significant advancements in molecular profiling technologies require continuous updates to clinical practice.
Conclusions:
- Molecular profiling is a cornerstone of modern precision medicine in oncology.
- Healthcare providers must stay informed about evolving molecular profiling techniques and standards.
- The future of cancer treatment lies in personalized approaches guided by comprehensive molecular data.
Related Concept Videos
Molecular and Ionic Solids
Molecular Solids
Molecular crystalline solids, such as ice, sucrose (table sugar), and iodine, are solids that are composed of neutral molecules as their constituent units. These molecules are held together by weak intermolecular forces such as London dispersion forces, dipole-dipole interactions, or hydrogen bonds, which...
Molecular Comparison of Gases, Liquids, and Solids
SI Units: 2019 Redefinition
A standard set of units has been defined...
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...

